Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO6870868 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| RO6870868 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RO6870868 | DRUG | Single ascending doses |
| placebo | DRUG | Single ascending doses |
Inclusion Criteria: * Healthy male and female subjects, 18 to 65 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history and a complete physical examination * Women of non-childbearing potential inc...
RO6870868 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in early clinical development. The completed Phase 1 trial evaluated its safety and tolerability in healthy adults, not for a specific medical condition.
RO6870868 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company conducted a Phase 1 study of the drug in healthy volunteers in the Netherlands.
RO6870868 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The single Phase 1 trial has been completed, and the drug is no longer in active clinical testing according to the available data.
RO6870868 has one completed clinical trial, NCT01911611, titled "A Study of RO6870868 in Healthy Volunteers." This Phase 1, randomized, double-blind, placebo-controlled study enrolled 60 healthy adults aged 18 years and older in the Netherlands.
No, RO6870868 is not FDA approved. It is an investigational drug that has only been studied in a Phase 1 clinical trial in healthy volunteers. The trial is completed, but the drug remains in clinical development and has not been approved for any use.